Dx & Vx Co

Dx & Vx Co FCF Yield

The Free Cash Flow Yield of Dx & Vx Co (180400.KQ) as of Nov 7, 2026 is -4.14 %. In the previous year, Free Cash Flow Yield was -4.26 % — a change of -2.83% (higher).

FCF Yield

-4.14 %

YoY

-2.83%

Last updated:

Free Cash Flow Yield of Dx & Vx Co is 2025 -4.14 % . Free Cash Flow Yield of Dx & Vx Co was 2024 -4.26 % . It decreases by -2.83% higher compared to the previous year.

The Dx & Vx Co FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2018
-1.86 KRW
Jan 1, 2019
-1.63 KRW
Jan 1, 2020
-1.49 KRW
Jan 1, 2021
-0.77 KRW
Jan 1, 2022
-0.18 KRW
Jan 1, 2023
-2.91 KRW
Jan 1, 2024
-4.26 KRW
Jan 1, 2025
-4.14 KRW
The Dx & Vx Co FCF Yield history
YEARFCF YieldYoY
-4.14 %-2.83%
-4.26 %+46.42%
-2.91 %+1,531.84%
-0.18 %-76.80%
-0.77 %-48.33%
-1.49 %-8.91%
-1.63 %-12.23%
-1.86 %+123.04%
-0.83 %+105.89%
-0.41 %+83.92%
-0.22 %-330.91%
0.10 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dx & Vx Co Stock analysis

What does Dx & Vx Co do? Dx & Vx Co., Ltd. generates revenue through the Molecular Diagnosis Business segment, which focuses on manufacturing and selling DNA chips, PCR chips, and related diagnostic reagents for molecular diagnosis. The company also produces enzymes and experimental reagents for biological research, targeting laboratories and healthcare facilities that require molecular diagnostic tools. Its products are sold to institutions involved in medical testing and research, leveraging the demand for advanced diagnostic solutions in healthcare. The company's revenue streams are derived from direct sales of these specialized products to the healthcare and research sectors. Dx & Vx Co., Ltd. operates within the molecular diagnostics market, offering DNA chips, PCR chips, and diagnostic reagents as core products. The company's focus on manufacturing and selling these items positions it as a provider of essential tools for molecular biology applications. Sales are directed toward laboratories and healthcare providers seeking to enhance their diagnostic capabilities through cutting-edge technology. The business model relies on consistent demand for molecular diagnostic equipment and reagents within the medical and research industries. Dx & Vx Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dx & Vx Co stock

Free Cash Flow Yield of Dx & Vx Co is -4.14 % in 2025.

Free Cash Flow Yield of Dx & Vx Co changed from -4.26 % to -4.14 %, representing a -2.83% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Dx & Vx Co since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Dx & Vx Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Dx & Vx Co

All Key Metrics — Dx & Vx Co